Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for moderate-to-severe atopic dermatitis in children ≥6 years (single-center, China)
ChiCTR2100050909Phase 4Recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Eczema Area and Severity Index 75 (EASI 75) and Investigator's Global Assessment (IGA) 0/1. Started Jul 2021; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2100050909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050909.